Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - amikacin, quantity: 500 mg (equivalent: amikacin sulfate, qty 667.5 mg) - injection, solution - excipient ingredients: sulfuric acid; sodium citrate dihydrate; sodium metabisulfite; water for injections - amikacin rmb injection is indicated in the short-term treatment of serious infections caused by susceptible strains of gram negative bacteria (see microbiology).,staphylococcus aureus, including methicillin resistant strains, is the principal gram positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.,amikacin rmb injection is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug maybe indicated because of the possibility of infections due to gram positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, postoperative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - amikacin sulfate - solution for injection - 250mg/1ml

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - amikacin, quantity: 500 mg - injection, solution - excipient ingredients: sodium citrate dihydrate; water for injections; sodium metabisulfite - dbl amikacin injection is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see section 5.1 pharmacodynamic properties).,staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.,dbl amikacin injection is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intraabdominal organs, post-operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - amikacin sulfate, quantity: 333.76 mg/ml (equivalent: amikacin, qty 250 mg/ml) - injection, solution - excipient ingredients: sodium citrate; water for injections; sulfuric acid; sodium metabisulfite - amiwok is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see microbiology).,staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of stapylococcus who have failed to respond or are allergic to other available antibiotics.,amiwok is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, post- operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

zoetis inc. - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin 250 mg in 1 ml - amiglyde-v is indicated for the treatment of uterine infections (endometritis, metritis and pyometra) in mares, when caused by susceptible organisms including escherichia coli , pseudomonas sp and klebsiell a sp. the use of amiglyde-v in eliminating infections caused by the above organisms has been shown clinically to improve fertility in infected mares. while nearly all strains of escherichia coli , pseudomonas sp and klebsiella sp, including those that are resistant to gentamicin, kanamycin or other aminoglycosides, are susceptible to amikacin at levels achieved following treatment, it is recommended that the invading organism be cultured and its susceptibility demonstrated as a guide to therapy. amikacin susceptibility discs, 30 mcg, should be used for determining in vitro susceptibility. there are no known contraindications for the use of amiglyde-v in horses other than a history of hypersensitivity to amikacin.

Παναμάς - Αγγλικά - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorio sanderson s.a. - amikacina (sulfato) - amikacina (sulfato)....500 mg*

Παναμάς - Αγγλικά - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

vitalis de panamÁ s.a. - amikacina (sulfato) - amikacina (sulfato)....500.00 mg

Μάλτα - Αγγλικά - Medicines Authority

norma hellas s.a. 54 menandrou str. gr-104 31 athens, greece - amikacin - solution for injection - amikacin 500 mg/2ml - antibacterials for systemic use

Σιγκαπούρη - Αγγλικά - HSA (Health Sciences Authority)

pharmaforte singapore pte ltd - amikacin sulfate eqv amikacin - injection - 500 mg/2 ml - amikacin sulfate eqv amikacin 500 mg/2 ml

Μάλτα - Αγγλικά - Medicines Authority

sopharma ad 16 iliensko shosse street, 1220 sofia, bulgaria - amikacin - solution for injection - amikacin 250 milligram(s)/millilitre - antibacterials for systemic use